Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Ferran Guedea

Phase II Trial of SBRT for Stage I NSCLC: Survival, Local Control, and Lung Function at 36 Months

Journal of Thoracic Oncology

English

Development and Refinement of a Technique Using a Medical Radiation Therapy Facility to Irradiate Immunodeficient Mice Bearing Xenografted Human Tumours

English

Related publications

Is the PTV Margin Important for Local Control in Stage I Non-Small Cell Lung Cancer (NSCLC) Patients Treated With Definitive SBRT?

International Journal of Radiation Oncology Biology Physics

English

OA06.05 Do SBRT Planning and Delivery Factors Influence Local Control for Early Stage Non-Small Cell Lung Cancer (E-Nsclc)?

Journal of Thoracic Oncology

English

SBRT for Early-Stage Glottic Larynx Cancer—Initial Clinical Outcomes From a Phase I Clinical Trial

PLoS ONE

Multidisciplinary

2017

English

Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated After Chemoradiotherapy and an 8-Year Update on a Phase I/Ii Trial

Clinical Cancer Research

Cancer Research

Oncology

2011

English

SBRT for Central Tumors in Early Stage NSCLC Patients

International Journal of Radiation Oncology Biology Physics

English

P3.17-12 Phase II Trial of Atezolizumab Before and After Chemoradiation for Unresectable Stage III NSCLC (AFT-16): Trial in Progress

Journal of Thoracic Oncology

English

SBRT Effective for Inoperable Early-Stage Lung Cancer

Cancer Discovery

Oncology

2014

English

640. AdCD40L Immunostimulatory Gene Therapy in Combination With Cyclophosphamide Prolongs 6-Months Survival in a Phase I/Ii Trial for Malignant Melanoma

English

P1.01-47 Phase I/Ii Trial of Dasatinib and Osimertinib in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Ferran Guedea

Phase II Trial of SBRT for Stage I NSCLC: Survival, Local Control, and Lung Function at 36 Months

Development and Refinement of a Technique Using a Medical Radiation Therapy Facility to Irradiate Immunodeficient Mice Bearing Xenografted Human Tumours

Related publications

Is the PTV Margin Important for Local Control in Stage I Non-Small Cell Lung Cancer (NSCLC) Patients Treated With Definitive SBRT?

OA06.05 Do SBRT Planning and Delivery Factors Influence Local Control for Early Stage Non-Small Cell Lung Cancer (E-Nsclc)?

SBRT for Early-Stage Glottic Larynx Cancer—Initial Clinical Outcomes From a Phase I Clinical Trial

Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated After Chemoradiotherapy and an 8-Year Update on a Phase I/Ii Trial

SBRT for Central Tumors in Early Stage NSCLC Patients

P3.17-12 Phase II Trial of Atezolizumab Before and After Chemoradiation for Unresectable Stage III NSCLC (AFT-16): Trial in Progress

SBRT Effective for Inoperable Early-Stage Lung Cancer

640. AdCD40L Immunostimulatory Gene Therapy in Combination With Cyclophosphamide Prolongs 6-Months Survival in a Phase I/Ii Trial for Malignant Melanoma

P1.01-47 Phase I/Ii Trial of Dasatinib and Osimertinib in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)